Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Cited by
Items 301–400 of 478
Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 11
“The conversion of isocitrate to a-KG by IDH1/2 generates a crucial reducing agent, NADPH, which plays a pivotal role in regulating cellular defense mechanisms against oxidative stress through reduction of glutamine metabolism [159].”
BackgroundThe emerging role of metabolic interventions in uveal melanoma
Kuranaga, Y., Hatem, Y., Grossniklaus, H. E., Ali, S. S., & Meir, E. G. V. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.002 · Cited by 10
A perioperative study of Safusidenib in patients with IDH1 -mutated glioma
Cain, S. A., Topp, M. D., Rosenthal, M. A., Tobler, R., Freytag, S., Best, S. A., Whittle, J. R., & Drummond, K. J. (2024) · Future Oncology · doi:10.1080/14796694.2024.2383064 · Cited by 10
“Excess production of 2-HG out c ompet es α -KG, inhibiting α -KG-dependent enzymes inv olv ed in epigenetic regulation, collagen synthesis and c ell sig naling, leading t o a block in differentiation of progenitor cells and subsequent development of cancer [ 17 , 18 ].”
BackgroundBabakoohi, S., Lapidus, R. G., Faramand, R. G., Sausville, E. A., & Emadi, A. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000342 · Cited by 9
“Key Words: isocitrate dehydrogenase, 2-hydroxyglutarate, AML, immunohistochemistry, magnetic resonance spectroscopy Isocitrate dehydrogenase 1 (IDH1) and IDH2 are locatedin the cytoplasm and mitochondrial matrix, respectively, and catalyze the conversion of isocitrate to a-ketoglutarate with reduction of NADP+ to NADP…”
BackgroundIDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
Mourad, S., Bilodeau, M., Roussy, M., Laramée, L., Boulianne, L., Rouette, A., Jouan, L., Gendron, P., Duval, M., Teira, P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00772 · Cited by 9
Estudio de mutaciones en los genes IDH1 e IDH2 en una muestra de gliomas de población colombiana
Ricaurte, O., Neita, K., Valero, D., Ortega-Rojas, J., Bustos, C., Zubieta, C., Penagos, J., & Arboleda, G. (2017) · Biomédica · doi:10.7705/biomedica.v38i0.3708 · Cited by 9
“En general, las mutaciones en los genes IDH1 e IDH2 se han asociado con un mejor pronóstico, una mayor supervivencia global libre de progresión y una mejor respuesta a la quimioterapia (7-9).”
BackgroundInfluentialTiburcio, P. D. B., Xiao, B., Chai, Y., Asper, S., Tripp, S. R., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26203 · Cited by 9
“com synthesis, and cell signaling [4].”
Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky
Liu, J., Murali, T., Yu, T., Liu, C., Sivakumaran, T. A., Moseley, H., Zhulin, I. B., Weiss, H. L., Durbin, E. B., Ellingson, S. R., et al. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0984 · Cited by 10
“As previously mentioned, certain variants of IDH1 are known to produce the oncometabolite 2HG, (38, 39) which showed inhibitory effects on 2OG-dependent enzymes, with the histone demethylases (KDM) most sensitive to inhibition (40).”
BackgroundZhang, Q., Yang, Y., Lu, Y., & Cao, Z. (2021) · Poultry Science · doi:10.1016/j.psj.2021.101111 · Cited by 9
Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs
Roessner, A., Franke, S., Schreier, J., Ullmann, S. R., Karras, F., & Jechorek, D. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154172 · Cited by 9
Sakamoto, T., Leca, J., Zhang, X., Meydan, C., Foox, J., Ramachandran, P., Hendrikse, L. D., Zhou, W., Berger, T., Fortin, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415779122 · Cited by 9
Self-citationZhu, Z., Yang, L., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07552-3 · Cited by 8
Zhang, W., Bai, H., Wang, Y., Wang, X., Jin, R., Guo, H., Lai, H., Tang, Y., & Wang, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17030336 · Cited by 8
“The somatic mutations of IDH1 play a pivotal role in the initiation and maintenance of various types of cancers [1,2], such as AML [3–5], intrahepatic cholangiocarcinoma [6], grade II–III gliomas [7], and secondary glioblastomas [8].”
BackgroundSandoval, C., Calle, Y., Godoy, K., & Farías, J. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076031 · Cited by 9
DNA Methylation and Hydroxymethylation in Cancer
Asmar, F., Helbo, A. S., & Grønbæk, K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00002-1 · Cited by 11
Validation of a multi-omics strategy for prioritizing personalized candidate driver genes
Liang, L., Song, L., Yang, Y., Tian, L., Li, X., Wu, S., Huang, W., Ren, H., Tang, N., & Ding, K. (2016) · Oncotarget · doi:10.18632/oncotarget.9540 · Cited by 10
“However, the hotspot R132H mutation was significantly under-represented in intrahepatic cholangiocarcinoma [41], suggesting a differential mutation pattern of IDH1 in different cancer types.”
BackgroundChiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective
Thamim, M., & Thirumoorthy, K. (2020) · European Biophysics Journal · doi:10.1007/s00249-020-01460-x · Cited by 8
“Such unexpected metabolites can then have different chemical reactivity in the cellular machinery (Cairns and Mak 2013; Yen et al. 2013; Pavlova and Thompson 2016).”
BackgroundMethodInfluentialIdentification of Novel Mutant (R132H) Isocitrate Dehydrogenase 1 Inhibitors for Glioma Therapy
Murali, P., & Ramanathan, K. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416522500260 · Cited by 8
Bund, C., Guergova-Kuras, M., Çiçek, A. E., Moussallieh, F., Dali‐Youcef, N., Piotto, M., Schneider, P., Heller, R., Entz‐Werlé, N., Lhermitte, B., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1522-5 · Cited by 8
Beyond the Oncogene Revolution: Four New Ways to Combat Cancer
Berger, T., Saunders, M. E., & Mak, T. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031161 · Cited by 9
Self-citationJones, R. L., Groisberg, R., Blay, J., Colman, H., Fuente, M. D. L., Roxburgh, P., Chao, M. M., Tian, H., Duffaud, F., Bahleda, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68716-6 · Cited by 7
“Mutated IDH proteins produce the metabolite D-2-hydroxyglutarate (2-HG) from α -ketoglutarate ( α -KG) conversion, whichaccumulatesandinhibitsthefunctionof enzymesdependenton α -KG, leading to oncogenesis and cancer progression 3,6,18 .”
Mitochondria of transformed cell as a target of antitumor influence
Frantsiyants, E. M., Neskubina, I. V., & Sheiko, E. A. (2020) · Research and Practical Medicine Journal · doi:10.17709/2409-2231-2020-7-2-9 · Cited by 8
Favre, L., Sako, N., Tarfi, S., Quang, V. T., Joy, C., Dupuy, A., Guillerm, E., Gaulard, P., Wagner‐Ballon, O., Pujals, A., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13311 · Cited by 7
Modrzejewska, M., Gawroński, M., & Gackowski, D. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114129 · Cited by 7
Holst, J. M., Enemark, M. B., Pedersen, M. B., Lauridsen, K. L., Hybel, T. E., Clausen, M. R., Frederiksen, H., Møller, M. B., Nørgaard, P. H., Plesner, T. L., et al. (2021) · Cancers · doi:10.3390/cancers13215526 · Cited by 7
“IDH2 protein mutants causing elevated 2HG are known to occur in several malignancies, including acute myeloid leukemia and AITL [28,31].”
BackgroundMiyake, K., Baba, Y., Ishimoto, T., Hiyoshi, Y., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., Ogata, Y., Nagayama, M., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1229-x · Cited by 7
Cai, X., Chen, Z., Huang, C., Shen, J., Zeng, W., Feng, S., Liu, Y. S., Li, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.950917 · Cited by 7
S-2HG is an immunometabolite that shapes the T-cell response
Cairns, R. A., & Mak, T. W. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.149 · Cited by 7
Self-citationWang, Y., Liu, X., Laurini, E., Posocco, P., Ziarelli, F., Fermeglia, M., Qu, F., Pricl, S., Zhang, C., & Peng, L. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00630e · Cited by 6
EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
Taher, M. M., Dairi, G., Butt, E., Alquthami, K. M., Alkhalidi, H., Jastania, R., Nageeti, T., Bogari, N. M., Athar, M., Al-Allaf, F. A., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12247 · Cited by 7
“The mutation of the IDH1 and IDH2 genes play an important role in gliomas by converting α‐ketoglutarate (α‐KG), which is produced in tricarboxylic acid (TCA) cycle, to an oncometabolite, 2‐HG (22).”
BackgroundQuantitative Analysis of Oncometabolite 2-Hydroxyglutarate
Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 6
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
Fang, Y., Wang, X., Luo, K., Dakal, T. C., Bai, H., Xu, C., & Zhang, G. (2026) · MedComm · doi:10.1002/mco2.70732 · Cited by 6
Chen, S., Zhu, H., Jin, M., Yuan, H., Liu, Z., Li, J., Zhang, X., Meng, L., Li, T., Diao, Y., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4764 · Cited by 6
Schoedel, K. E., Heim, T. E., Duensing, A. U., Lohse, I., Presutti, L., Belayneh, R., Bhogal, S. S., Singh‐Varma, A., Chang, A., Chandran, U. R., et al. (2024) · Cancers · doi:10.3390/cancers16020247 · Cited by 5
“Mutations in IDH1/2 are thought to be oncogenic through the aberrant production of D2-hydroxyglutarate (D2-HG) [7].”
BackgroundYu, Y., Gan, W., Xiong, J., & Li, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37344 · Cited by 5
“Isocitrate dehydrogenase 1 (IDH1) catalyses the production of α -ketoglutarate and NAPDH from isocitrate, which are involved in cellular energy metabolism and biosynthesis [20].”
BackgroundWang, Y., Assaf, Z., Liu, X., Ziarelli, F., Latifi, A., Lamrabet, O., Quéléver, G., Qu, F., Zhang, C., & Peng, L. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01005a · Cited by 5
Intraoperative mass spectrometry of tumor metabolites
Pope, W. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410871111 · Cited by 6
Expression patterns of members of the isocitrate dehydrogenase gene family in murine inner ear
Kim, Y.-R., Kim, K.-H., Lee, S., Oh, S.-K., Park, J.-W., Lee, K., Baek, J.-I., & Kim, U. (2017) · Biotechnic & Histochemistry · doi:10.1080/10520295.2017.1367034 · Cited by 5
“A deficiency of Idh genes can produce significant alterations of phenotypes (Dang et al. 2009, Yang et al. 2012, Cairns and Mak 2013, Losman and Kaelin 2013).”
BackgroundVarachev, V. O., Guskov, D. A., Shekhtman, A. P., Рогожин, Д. В., Polyakov, S. A., Zacedatelev, A. S., Chudinov, A. V., & Nasedkina, T. V. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023050205 · Cited by 5
Zhao, Y. (2019) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/332/3/032023 · Cited by 5
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 5
Yu, J. B., Sun, J., Du, Y., Patel, R. D., Varela, J. C., Mori, S., & Chang, C.-C. (2021) · Diagnostics · doi:10.3390/diagnostics11060986 · Cited by 5
“It is well established that IDH1 and 2 are mutually exclusively in AML [21].”
BackgroundNagaoka, K., Bai, X., Liu, D., Cao, K. Y., Mulla, J., Ji, C., Chen, H., Nisar, M. A., Bay, A., Mueller, W., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216493 · Cited by 5
Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy
Hua, S., Fei, F., Li, J., Liu, Y., Gao, Y., Wang, X., Dong, X., Liu, Q., & Yang, J. (2026) · Cell Death Discovery · doi:10.1038/s41420-025-02843-9 · Cited by 4
“[ 134 ] P T P N 3 ( L 232 R m u t a t i o n ) T h e L 232 R m u t a t i o n i n P T P N 3 e nh a n c e s T G F - β s i gn a li ng a n d b l o c k s i t s t u m o r s u pp r e ss o r f u n c t i o n .”
Weigel, C., Klimaszewski, H., Tounkara, F., Addissie, S., Schlotter, S. Y., Pray, B. A., Dugan, J. P., Haverkos, B. M., Villagomez, L., Lustberg, M. E., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100200 · Cited by 4
“We validated these findings in a second model of TET deficiency that relied on the overexpression of mutant isocitrate dehydrogenase 1 (IDH1, R132H), which impairs all 3 TET family members by generating α -hydroxyglutarate 43 to target enzymatic activity directly.”
Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells
Morishima, T., Takahashi, K., Chin, D. W. L., Wang, Y., Tokunaga, K., Arima, Y., Matsuoka, M., Suda, T., & Takizawa, H. (2023) · Cancer Science · doi:10.1111/cas.15994 · Cited by 4
Fighting Fire with Fire in Cancer
Berger, T., Saunders, M. E., & Mak, T. W. (2015) · Springer eBooks · doi:10.1007/978-4-431-55651-0_3 · Cited by 4
“D2HG has been shown in vitro to competitively inhibit 2OGD [52], and the high concentration of D2HG measured in cells and tissues of IDH-mutant tumors makes it very likely that D2HG impairs the activity of this class of enzymes in vivo as well [36].”
BackgroundInfluentialSelf-citationDiminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors
Huang, C., Fischer, C., Machacek, M. R., Bogen, S. L., Biftu, T., Huang, X., Reutershan, M. H., Otte, R. D., Hong, Q., Wu, Z., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00089 · Cited by 4
IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders (Review)
Ya, G., Wei, S., Wei, Y., Chen, Y., Cui, J. T., Yu, Y., Lin, X., Yan, H., Qin, H., & Yi, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13398 · Cited by 4
“Mutations in the IDH2 potein often occur in arginine residues R140 and R172, and are closely associated with the development and progression of AML and glioma (13).”
BackgroundLai, C., Leahy, T. P., Turner, A. J., Thomassen, A., Wang, L., Sheppard, A. D., & Cortes, J. E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2514894 · Cited by 5
“IDH1 gene mutations, present in 7%–14% of patients with AML [4–6], promote transformation of α-KG to 2-hydroxyglutarate (2-HG), which can promote neoplastic transformation in the case of aberrant accumulation [7–9].”
Challenging Roadblocks to Cancer Cure
Loda, M. F. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1443 · Cited by 4
Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach
Juritz, E., Bascur, J. P., Almonacid, D. E., & González-Nilo, F. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0331-2 · Cited by 4
Echeverría, O., Patiño-Aldana, A. F., Chinchilla, A., Contreras, N., Peralta, S., Caballero, N., Tovar, H. V., Palacio, J. M., Uribe, V., Mineo-Pachón, M., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1691983 · Cited by 3
“Proper genotyping of both IDH1 and IDH2 is necessary to achieve the correct diagnosis, prognosis and therapeutic options involving IDH mutant inhibitors (37).”
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer
Choubey, P., Kaur, H., & Bansal, K. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_7 · Cited by 3
Prognostic impact of co-mutations in adults with IDH1/2-mutated acute myeloid leukemia
Lai, A., Liu, W., Zhou, C., Li, Y., Wei, S., Liu, K., Gong, B., Gong, X., Liu, Y., Zhang, G., et al. (2025) · Blood Science · doi:10.1097/bs9.0000000000000231 · Cited by 3
Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression
Ing‐Simmons, E., & Merkenschlager, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.008 · Cited by 3
Esumi, H. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00362.2013 · Cited by 4
A Nexus model of cellular transition in cancer
Yadav, M., Chatterjee, P., Tolani, S., Kulkarni, J. L., Mulye, M., Chauhan, N., Sakhi, A., & Gorey, S. (2018) · Biological Research · doi:10.1186/s40659-018-0173-8 · Cited by 2
The Distribution and Significance of IDH Mutations in Gliomas
Tran, N. T. N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.97380 · Cited by 2
Current trends in Glioblastoma
Koçak, M., Atasoy, Ö., Çini, N., & Erbaş, O. (2021) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2021.25074 · Cited by 2
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition
Piva, R., Gharari, N., Labrador, M., & Mader, S. (2024) · Cancers · doi:10.3390/cancers16193280 · Cited by 2
Tsai, Y.-H., Cheng, W.-Y., Huang, B.-H., Shen, C., & Tsai, M. (2025) · Electronics · doi:10.3390/electronics14122498 · Cited by 2
Zinc toxicity induces intestinal cell death via inhibiting NAD+ synthesis in mice and IPEC-J2 cells
Chen, L., Huang, F., Zhu, L., Tian, X., Zhou, M., & Feng, J. (2025) · Animal Nutriomics · doi:10.1017/anr.2025.10008 · Cited by 2
Active DNA Demethylation in Development, Human Disease, and Cancer
Tricarico, R., & Bellacosa, A. (2016) · Springer eBooks · doi:10.1007/978-4-431-55873-6_21 · Cited by 2
Bagacean, C., Bordron, A., Tempescul, A., Ianotto, J., Guillerm, G., Brooks, W. H., Couturier, M., Zdrenghea, M., Berthou, C., & Renaudineau, Y. (2018) · OBM Genetics · doi:10.21926/obm.genet.1804054 · Cited by 3
Epigenetic Alterations in Colorectal Cancer
Ko, B., Hanna, M., Yu, M., & Grady, W. M. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_10 · Cited by 2
THE EFFECTS OF METFORMIN ON PANCREATIC CANCER METABOLISM
Cantoria, M. J. (2014) · UA Campus Repository (The University of Arizona) · Cited by 2
Song, Y., Wang, Z., Xu, L., Han, B., & Sun, D. (2024) · Life · doi:10.3390/life14101228 · Cited by 1
“This enzyme is believed to have critical functions in glucose metabolism, fatty acids metabolism, and glutamine metabolism [24,25].”
BackgroundYang, Y., Nie, Y., Wu, R., Han, R., Zhao, Y., Yang, R., Yuan, Y., Gao, X., Chen, H., Zhang, F. L., et al. (2025) · Antioxidants and Redox Signaling · doi:10.1177/15230864251394709 · Cited by 1
“In the absence of Cre-recombinase (Cre) expression, the LSL IDH1R132Q mutant allele is null, but when Cre is expressed, the stop codon upstream of exon 4 is excised and the mutant IDH1 protein is expressed from the endogenous locus (Cairns and Mak, 2013; Drummond and Kappas, 1986; Gu et al., 2021).”
Gharari, N., Mereu, E., Luciano, B., Heidari, B., Mader, S., & Piva, R. (2026) · Cancers · doi:10.3390/cancers18030368 · Cited by 1
“…of the oncometabolite 2-hydroxyglutarate, the majority of solid tumors predominantly express the wild-type enzyme, which functions not as a direct oncogenic driver but as a metabolic safeguard supporting mitochondrial redox balance and biosynthetic capacity under oncogenic stress [10,11].”
Shuai, Y., Ruiter, R., Stricker, B. H. C., Ikram, M. A., & Ghanbari, M. (2026) · Metabolomics · doi:10.1007/s11306-026-02397-6 · Cited by 1
“(Cairns & Mak, 2013 ).”
Discovery of a new binding site and a possible gain in neomorphic activity in R132H_IDH1
Nandeshwar, Biswal, A. S., Chatterjee, S., & Tripathy, U. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp04261e · Cited by 1
Josephine, A., Kumar, S. A., Varalakshmi, S., & Rajendran, P. (2026) · 3 Biotech · doi:10.1007/s13205-026-04753-8 · Cited by 1
Huang, Y., Wei, Y., Xie, S., Li, Q., Zhou, F., Ma, Y., Ruan, Y., Ji, S., Wang, J., & Shen, X. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.03.055 · Cited by 1
Advanced nanomaterials for dehydrogenase-based electrochemical sensing: A comprehensive review
Aslam, M., Bhola, R., Anadebe, V. C., Shukla, S., Ebenso, E. E., Kumari, K., Meghvansi, M. K., & Singh, P. (2026) · Sensors and Actuators Reports · doi:10.1016/j.snr.2026.100494 · Cited by 2
Pulmonary Hypertension as a Metabolic Disease
Fessel, J. P., & Oldham, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_8 · Cited by 1
Kranz, L. M., Birtel, M., Krienke, C., Grunwitz, C. R., Petschenka, J., Reuter, K. C., van de Roemer, N., Vascotto, F., Vormehr, M., Kreiter, S., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1068485 · Cited by 2
Molecular Drivers in Chondrosarcoma
de Jong, Y., & Bovée, J. V. M. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804257-1.00004-9 · Cited by 1
Platten, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_39 · Cited by 1
Prognostic markers in acute myeloid leukemia : A candidate gene approach
Falk, I. J. (2018) · Linköping University medical dissertations · doi:10.3384/diss.diva-153476 · Cited by 1
Pharmacoepigenetics of Systemic Lupus Erythematosus
Hedrich, C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00021-8 · Cited by 2
New Emerging Molecules in Cancer Research Which Hold Promise in Current Era
Bhatia, D. R., Rath, S., & Gupta, S. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_20 · Cited by 1
Huang, F., Tian, T., Wu, Y., Che, J., Yang, H., & Dong, X. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201130102724 · Cited by 1
Mechanisms of T‐cell Lymphomagenesis
Lemonnier, F., Gaulard, P., & de Leval, L. (2021) · Wiley eBooks · doi:10.1002/9781119671336.ch2 · Cited by 1
Dico, A. L., Salvatore, D., Diceglie, C., Martelli, C., & Ottobrini, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00026-9 · Cited by 1
Yip, S. S. F., & Blakeley, J. O. (2014) · Molecular pathology library · doi:10.1007/978-1-4939-1830-0_8 · Cited by 1
Mitochondrial Energy Metabolism in Carcinogenesis
Kurhaluk, N., & Tkaczenko, H. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_226 · Cited by 2
Epigenetic Biomarkers in Personalized Medicine
Coppedè, F., Lopomo, A., & Migliore, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420135-4.00007-3 · Cited by 1
Bayık, D., Lauko, A. J., Roversi, G. A., Serbinowski, E., Acevedo-Moreno, L.-A. G., Lanigan, C. P., Orujov, M., Lo, A., Alban, T. J., Silver, D. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/554600 · Cited by 1
Desenvolvimento de radiotraçadores angiogênicos para diagnóstico de glioma: estudo em modelo animal
de Oliveira, E. A. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.85.2014.tde-02122014-143353
Willander, K. (2014) · Linköping University Electronic Press eBooks · doi:10.3384/diss.diva-104951
DNA Methylation as a Biomarker in Cancer
Fukushige, S., & Horii, A. (2015) · Biomarkers in disease · doi:10.1007/978-94-007-7681-4_45
Contingent microARN des exosomes, diagnostic et physiopathologie des gliomes
Ipas, H. (2013) · theses.fr (ABES) · doi:10.70675/26c41171z1eafz4a32z9b02z84f3482879ac
CIC Mutation as Signature Alteration in Oligodendroglioma
Ahmad, S. T., Wu, W., & Chan, J. A.-W. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_24
Chromatin Dynamics and Epigenetics of Stem Cells and Stem-Like Cancer Cells
Gaspar‐Maia, A., & Sevilla, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802389-1.00017-4
A Journey in Science: “Not Lost in Translation”
Mak, T. W. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00176
Self-citationL’intrication des voies métaboliques dans la progression tumorale
Larsen, C. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1816
Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology
Robey, R. B. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch15 · Cited by 1
Advances in Sarcoma Genomics and Therapeutic Management
Somasundaram, N., Chan, S. H., Quek, R. H. H., & Ngeow, J. Y. Y. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00043-0 · Cited by 1
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.